Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS (Leukemia, (2020), 34, 7, (1751-1759), 10.1038/s41375-020-0725-0)

Autor: Ossenkoppele, G. J., Breems, D. A., Stuessi, G., van Norden, Y., Bargetzi, M., Biemond, B. J., A von dem Borne, P., Chalandon, Y., Cloos, J., Deeren, D., Fehr, M., Gjertsen, B. T., Graux, C., Huls, G., Janssen, J. J.J.W., Jaspers, A., Jongen-Lavrencic, M., de Jongh, E., Klein, S. K., Van der Klift, M., Van Marwijk Kooy, M., Maertens, J., Michaux, L., van der Poel, M. W.M., Van Rhenen, A., Tick, L., Valk, P., Vekemans, M. C., van der Velden, W. J.F.M., de Weerdt, O., Pabst, T., Manz, M., Löwenberg, B., Havelange, Moors, I., van Obberg, F., Maertens, J. A., Hodossy, B., Vansteenweghen, S., Lammertijn, L., Sonet, A., Triffet, A., Passweg, J., Heim, D., Giovanni, San, Stuessi, Georg, Betticher, D., Spertini, O., Gregor, M., Hess, U., Manz, M. G., van de Loosdrecht, A., Janssen, J. J.W.M., van Esser, J. W.J., Brouwer, R. E., Van Lammeren-Venema, D., Levin, M. D., Tick, L. W., Legdeur, M. C.J.C., Vellenga, E., Hoogendoorn, M., Veelken, J. H., von dem Borne, P. A., Schouten, H. C., Cornelissen, J., Wouters, B., Raaijmakers, H. G.M., Kuball, J.

Publikováno v: Leukemia, 34(10). Nature Publishing Group
Ossenkoppele, G J, Breems, D A, Stuessi, G, van Norden, Y, Bargetzi, M, Biemond, B J, A von dem Borne, P, Chalandon, Y, Cloos, J, Deeren, D, Fehr, M, Gjertsen, B T, Graux, C, Huls, G, Janssen, J J J W, Jaspers, A, Jongen-Lavrencic, M, de Jongh, E, Klein, S K, Van der Klift, M, Van Marwijk Kooy, M, Maertens, J, Michaux, L, van der Poel, M W M, Van Rhenen, A, Tick, L, Valk, P, Vekemans, M C, van der Velden, W J F M, de Weerdt, O, Pabst, T, Manz, M, Löwenberg, B, Breems, D A, Havelange, Vekemans, M C, Moors, I, van Obberg, F, Maertens, J A, Hodossy, B, Vansteenweghen, S, Lammertijn, L, Deeren, D, Graux, C, Sonet, A, Triffet, A, Gjertsen, B T, Bargetzi, M, Passweg, J, Heim, D, Giovanni, S, Stuessi, G, Pabst, T, Betticher, D, Chalandon, Y, Spertini, O, Gregor, M, Hess, U, Fehr, M, Manz, M G, Klein, S K, Biemond, B J, Ossenkoppele, G J, van de Loosdrecht, A, Janssen, J J W M, van Esser, J W J, Van der Klift, M, Brouwer, R E, Van Lammeren-Venema, D, Levin, M D, Tick, L W, Legdeur, M C J C, Huls, G, Vellenga, E, Hoogendoorn, M, Veelken, J H, von dem Borne, P A, Schouten, H C, de Weerdt, O, van der Velden, W J F M, Cornelissen, J, Jongen-Lavrencic, M, Wouters, B, Raaijmakers, H G M, Löwenberg, B, Kuball, J, Van Rhenen, A, Van Marwijk Kooy, M & for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) 2020, ' Correction : Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS (Leukemia, (2020), 34, 7, (1751-1759), 10.1038/s41375-020-0725-0) ', Leukemia, vol. 34, no. 10 . https://doi.org/10.1038/s41375-020-0994-7

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::4231d8d48f8da424335ae95804aeb6bc
https://research.vumc.nl/en/publications/05f113e6-d597-4250-99cf-855010361d8a

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

LEUKEMIC STEM CELL FREQUENCY COMBINED WITH MRD IS AN IMPORTANT BIOMARKER TO PREDICT RELAPSE IN ACUTE MYELOID LEUKEMIA. RESULTS FROM A PROSPECTIVE H102 STUDY

Autor: Zeijlemaker, W., Meijer, R., Kelder, A., Carbaat-Ham, J., Oussoren-brockhoff, Y., Snel, S., Veldhuizen, D., Scholten, W., Maertens, J., Breems, D., Pabst, T., Manz, M., Van der Velden, V., Slomp, J., Valk, P., Cloos, J., Lowenberg, B., Ossenkoppele, G., Schuurhuis, G. J.

Publikováno v: Haematologica, 102, 7-8. Ferrata Storti Foundation
Zeijlemaker, W, Meijer, R, Kelder, A, Carbaat-Ham, J, Oussoren-brockhoff, Y, Snel, S, Veldhuizen, D, Scholten, W, Maertens, J, Breems, D, Pabst, T, Manz, M, Van der Velden, V, Slomp, J, Valk, P, Cloos, J, Lowenberg, B, Ossenkoppele, G & Schuurhuis, G J 2017, ' LEUKEMIC STEM CELL FREQUENCY COMBINED WITH MRD IS AN IMPORTANT BIOMARKER TO PREDICT RELAPSE IN ACUTE MYELOID LEUKEMIA. RESULTS FROM A PROSPECTIVE H102 STUDY ', Haematologica, vol. 102, pp. 7-8 .

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::f8515beed5f976fea07915d6a81557ac
https://research.vumc.nl/en/publications/08b5a729-d702-4e0f-8323-80bff0bf497f

Stroma-conditioned media improve expansion of human primitive hematopoietic stem cells and progenitor cells.

Autor: Breems, D A, Blokland, E A W, Ploemacher, R E, Blokland, E A (AUTHOR)

Publikováno v: Leukemia (08876924). Jan97, Vol. 11 Issue 1, p142-150. 9p.

P366: BLINATUMOMAB ADDED TO PREPHASE AND CONSOLIDATION THERAPY IN NEWLY DIAGNOSED PRECURSOR B‐ALL IN ADULTS. A PHASE II HOVON TRIAL.

Autor: Rijneveld, A., Gradowska, P., Bellido, M., de Weerdt, O., Gadisseur, A., Deeren, D., van der Wagen, L., Jauw, Y., Fijnheer, R., van Lammerren, D., Selleslag, D., Halkes, S., Biemond, B., Breems, D., Moors, I., van Sluis, G., Bakkus, M., Homburg, C., Janda, V., van der Velden, V.

Publikováno v: HemaSphere; 2022 Supplement 3, Vol. 6, p266-267, 2p